Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (trading symbol: OCX) on March 31, 2023. The filing serves to announce the company's preliminary financial results for the three and twelve months ended December 31, 2022. The registrant is incorporated in California and its common stock is listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K document.
Material Changes
No specific material changes or comparative financial data versus prior periods are disclosed in the text of this filing. The document solely references the issuance of a press release containing the preliminary results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be deemed incorporated by reference into other filings unless expressly stated. No specific guidance, management commentary, risks, or contingencies are detailed in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 31, 2023) for the actual preliminary financial figures for the periods ended December 31, 2022.
- Verify the company's current cash position and burn rate, as these are not listed in the 8-K summary text.
- Confirm whether the preliminary results indicate any material deviations from previously issued guidance.
- Check for any subsequent filings that may provide audited or more detailed financial statements.